90 related articles for article (PubMed ID: 17151370)
1. Another look at imatinib mesylate.
Strebhardt K; Ullrich A
N Engl J Med; 2006 Dec; 355(23):2481-2. PubMed ID: 17151370
[No Abstract] [Full Text] [Related]
2. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Kerkelä R; Grazette L; Yacobi R; Iliescu C; Patten R; Beahm C; Walters B; Shevtsov S; Pesant S; Clubb FJ; Rosenzweig A; Salomon RN; Van Etten RA; Alroy J; Durand JB; Force T
Nat Med; 2006 Aug; 12(8):908-16. PubMed ID: 16862153
[TBL] [Abstract][Full Text] [Related]
3. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate induced skin hypopigmentation.
Talwar V; Doval DC; Bhatia K
J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
[No Abstract] [Full Text] [Related]
5. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Rosti G; Martinelli G; Baccarani M
Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
[No Abstract] [Full Text] [Related]
6. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Atallah E; Kantarjian H; Cortes J
Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
[No Abstract] [Full Text] [Related]
7. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Hatfield A; Owen S; Pilot PR
Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
[No Abstract] [Full Text] [Related]
8. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
[No Abstract] [Full Text] [Related]
9. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
10. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
11. Eph tumour suppression: the dark side of Gleevec.
Wang JY
Nat Cell Biol; 2006 Aug; 8(8):785-6. PubMed ID: 16880809
[No Abstract] [Full Text] [Related]
12. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
Verweij J; Casali PG; Kotasek D; Le Cesne A; Reichard P; Judson IR; Issels R; van Oosterom AT; Van Glabbeke M; Blay JY
Eur J Cancer; 2007 Apr; 43(6):974-8. PubMed ID: 17336514
[TBL] [Abstract][Full Text] [Related]
13. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
14. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
15. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW; Druker BJ
Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
[TBL] [Abstract][Full Text] [Related]
16. Primary ovarian insufficiency associated with imatinib therapy.
Christopoulos C; Dimakopoulou V; Rotas E
N Engl J Med; 2008 Mar; 358(10):1079-80. PubMed ID: 18322295
[No Abstract] [Full Text] [Related]
17. Imatinib and pregnancy.
Ali R; Ozkalemkas F; Ozcelik T; Ozkocaman V; Ozkan A
J Clin Oncol; 2006 Aug; 24(23):3812-3; author reply 3813. PubMed ID: 16896012
[No Abstract] [Full Text] [Related]
18. Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?
Distler JH; Distler O
Ann Rheum Dis; 2007 Jun; 66(6):836. PubMed ID: 17513571
[No Abstract] [Full Text] [Related]
19. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
20. New-age drug meets resistance.
McCormick F
Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
[No Abstract] [Full Text] [Related]
[Next] [New Search]
